Table 1 Patients with primary cervical lymphoma treated in Yuhuangding Hospital
Patients | Age (y) | Manifestations | LDH (U/ml) | Treatment | Pathology | Stage | R | Treatment at R | Result of follow-up |
|---|---|---|---|---|---|---|---|---|---|
1 | 66 | Hematuria | 543 | R-CHOP*6 | DLBCL | IVE | Not CR | Partial remission and stable disease for 5 months then disease progress and die | DOD at 8 m |
2 | 72 | Back pain | 356 | R-CHOP*5, EBRT | DLBCL | IE | N | NED at 97 m | |
3 | 56 | Abdominal pain | 289 | TAH + BSO + pelvic and para-aortic lymphadenectomy; R-EPOCH*9, with intrathecal injection of Ara-C + DXM for 3 cycles | DLBCL | IVE | N | NED at 12 m | |
4 | 62 | Pelvic mass | 861 | Refusing treatment | DLBCL | IVE | Not CR | Rapidly progress and die | DOD at 1.5 m |
5 | 31 | Lower limb pain | 956 | R-hyperCVAD*3, R-MA*2, CVP-R*1 | Burkitt lymphoma | IVE | Y | R-hyperCVAD*4 with intrathecal injection of Ara-C + DXM, partial remission | AWD at 6 m |
6 | 58 | Back pain | 280 | R-CHOP*8 | DLBCL | IVE | N | NED at 27 m | |
7 | 71 | AUB | 586 | R-CHOP*6 (4 with Ara-C + DXM intrathecal injection) | DLBCL | IVE | Not CR | Partial remission and stable disease for 21 months, then disease progress, administered with R-CHOP*8, Oxaliplatin + gemcitabine for 3 cycles | DOD at 38 m |
8 | 58 | AUB | 429 | R-CHOP*8 (Ara-C + MTX intrathecal injection *4) | DLBCL | IE | N | NED at 88 m |